Balaxi Pharmaceuticals (BALAXI) Q1 24/25 earnings summary

Executive summary

• Focused on branded IPR-driven pharma in frontier markets, with leadership in Latin America and Africa and a strong branded generics portfolio.

• Transitioning from an asset-light to asset-right model by establishing its first manufacturing facility in Hyderabad, targeting backward integration and global expansion.

• Approved unaudited standalone and consolidated financial results for the quarter ended June 30, 2024.

• Board approved an equity infusion of up to USD 5 million in wholly owned subsidiary Balaxi Global Dubai DMCC to support operational and business expansion.

• Expanded product registrations to 989 across eight countries, with 700+ more in the pipeline, aiming to increase market share.

Financial highlights

• Q1 FY25 consolidated revenue was ₹65.62 crore, down 0.5% year-over-year; gross profit rose 7.2% to ₹27.48 crore.

• Q1 FY25 gross margin improved by 300 bps to 41.9%; EBITDA before exceptional items up 14.4% to ₹10.08 crore.

• Q1 FY25 PAT was ₹6.48 crore, a turnaround from a loss of ₹41.34 crore in Q1 FY24 (which included a ₹46.67 crore exceptional item).

• FY24 revenue declined 28.3% year-over-year to ₹241.29 crore; gross margin increased to 46.7% from 39.8%.

• FY24 EBITDA dropped 90% to ₹5.79 crore; PAT was negative at ₹2.39 crore, impacted by currency losses in Angola.

Outlook and guidance

• Anticipates robust growth through deeper market penetration, expansion into new frontier markets, and leveraging backward integration.

• Expects positive performance driven by new product launches, expanded distribution, and the upcoming Hyderabad facility.

• The USD 5 million investment in Balaxi Global Dubai DMCC is aimed at supporting working capital and expansion, indicating a focus on international growth.